Becton, Dickinson and Company (BDX) Q2 FY25 earnings call

Becton, Dickinson and Company reported Q2 FY25 organic revenue growth of 0.9%, falling short of expectations due to reduced research funding in Bioscience and slower recovery in BACTEC blood culture testing. Despite top-line challenges, the company exceeded adjusted EPS expectations, delivering 5.7% growth, fueled by significant gross and operating margin expansion from BD Excellence initiatives. Management is taking decisive actions to reaccelerate growth in the second half, including strategic investments and new product launches, while navigating tariff impacts and progressing with the Life